Skip to main content
CVRX
NASDAQ Life Sciences

CVRx Cuts Full-Year Revenue Guidance After Q3 Sales Slip 6%

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.47
Mkt Cap
$39.163M
52W Low
$1.255
52W High
$10.63
52W Position info
17% above low
Off High info
86% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CVRX sits 17% above its 52-week low of $1.255 on light trading volume (0.4× avg).

Summary

Q3 revenue came in at $13.8 million, down 6% from a year ago, with U.S. revenue of $13.0 million off 4% on lower sales force productivity and a prolonged challenge with one of its largest payers. Management cut full-year 2026 revenue guidance to $56.0-$57.0 million from $58.0-$60.0 million, and the Q4 guide of $11.7-$12.7 million implies a further sequential step down, with full-year gross margin guided to 86%-87% and operating expenses of $99-$101 million. The net loss widened to $14.2 million, or $0.52 per share, from $12.9 million a year earlier, while cash stood at $58.7 million against $11.0 million of quarterly cash burn. The lone bright spot is reimbursement: a second major Medicare Advantage payer issued a Barostim coverage policy, and the two policies together cover roughly 21% of MA enrollment. This lands after a rough stretch — the August CRO termination, a securities-fraud investigation, and activist Jorey Chernett exiting his 5.5% stake in October — so the guidance cut reinforces the execution concerns. New CFO John Landry starts November 6, and the 4:30 p.m. ET call today is where management will have to defend the demand shortfall.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — CVRx set Q4 2026 revenue guidance at $11.7-$12.7 million and full-year gross margin at 86%-87% with operating expenses of $99-$101 million.

At the time of this announcement, CVRX was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.2M. The 52-week trading range was $1.26 to $10.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CVRX - Latest Insights

CVRX
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5012 info
Change: -$0.9688 (-66%) info
Market Cap: $14.271M info
CVRX
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.5012 info
Change: -$0.9688 (-66%) info
Market Cap: $14.271M info
CVRX
Oct 02, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $0.5012 info
Change: -$1.03 (-67%) info
Market Cap: $14.271M info
CVRX
Sep 21, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.97
Real-time Price: $0.5012 info
Change: -$2.47 (-83%) info
Market Cap: $14.271M info
CVRX
Aug 24, 2026, 8:00 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $3.12
Real-time Price: $0.5012 info
Change: -$2.62 (-84%) info
Market Cap: $14.271M info